Use of stabilized oligonucleotides for preparing a...

Details Use of stabilized oligonucleotides for preparing a... Use of stabilized oligonucleotides for preparing a...

2006-09-19

2006-09-19

Huff, Sheela (Department: 1643)

Drug, bio-affecting and body treating compositions

Radionuclide or intended radionuclide containing; adjuvant...

C514S04400A, C536S023100, C536S024200

Reexamination Certificate

active

07108844

ABSTRACT:
The invention concerns the use of stabilized oligonucleotides comprising at least an octamer motif of the type: 5′-purine-purine-CG-pyrimidine-pyrimidine-X1X2-3′ wherein the pair X1-X2- is AT, AA, CT or TT, for preparing a medicine with antitumor activity.

REFERENCES:
patent: 5663153 (1997-09-01), Hutcherson et al.
patent: 5723335 (1998-03-01), Hutcherson et al.
patent: 5734033 (1998-03-01), Reed
patent: 6001982 (1999-12-01), Ravikumar et al.
patent: 6020475 (2000-02-01), Capaldi et al.
patent: 6022691 (2000-02-01), Bruice et al.
patent: 6069243 (2000-05-01), Scozzari
patent: 6121437 (2000-09-01), Guzaev et al.
patent: 6153737 (2000-11-01), Manoharan et al.
patent: 6160109 (2000-12-01), Just et al.
patent: 6160152 (2000-12-01), Capaldi et al.
patent: 6166239 (2000-12-01), Manoharan
patent: 6169177 (2001-01-01), Manoharan
patent: 6194388 (2001-02-01), Krieg et al.
patent: 6207646 (2001-03-01), Krieg et al.
patent: 6218371 (2001-04-01), Krieg et al.
patent: 6239116 (2001-05-01), Krieg et al.
patent: 6429199 (2002-08-01), Krieg et al.
patent: 0 468 520 (1990-07-01), None
patent: 0 855 184 (1997-01-01), None
patent: WO 94/25588 (1993-04-01), None
patent: WO 96/02555 (1994-07-01), None
patent: WO 97/44346 (1996-05-01), None
patent: WO 98/18810 (1996-10-01), None
patent: WO 98/55495 (1997-06-01), None
patent: WO 99/12027 (1997-08-01), None
patent: WO 99/26634 (1997-11-01), None
patent: WO 99/51259 (1998-04-01), None
patent: WO 00/62923 (1998-06-01), None
patent: WO 00/16804 (1998-09-01), None
patent: WO 00/21556 (1998-10-01), None
US 6,008,200, 12/1999, Krieg (withdrawn)
Donnelly J. Nature Medicine, 11(9): 1354-1356, Nov. 2003.
DeGruijl T. D. et al. Nature Medicine, 5(10): 1124-1125, Oct. 1999.
Jain R. K. Scientific American, 271(1):58-65, Jul. 1994.
Vile et al. Gene Therapy, (7):2-8, 2000.
Rochiltz C. F. Swiss Medicine Weekly, 131:4-9, 2001.
Verma et al. Nature, vol. 389(6648):239-242, 1997.
Britton R. J. Current Opinion in Molecular Therapeutics, 6(1):17-25, 2004.
Weiner G. J. Journal of Leukocyte Biology, 68:455-463, 2000.
Lonsdorf et al. The Journal of Immunology, 171:3941-3946, 2003.
Quan et al. Disease-a-Month, 43(11);745-808, 1997.
Tachibana et al. Tokai Journal of Experimental Clinical Medicine, 8(5-6):455-463, 1983.
Ballas, Zuhair K. et al., “Induction of NK Activity in Murine and Human Cells by CpG Motifs in Oligodeoxynucleotides and Bacterial DNA,” J. of Immunol. 1996, 157: 1840-1845.
Ishizaka, Y. et al., “Humanretproto-oncogene mapped to chromosome 10q11.2,” Nat'l Cancer Res. Instit. Aug. 17, 1989 (Short Report).
LaPlanche, Laurine A. et al., “Phosphorothioate-modified oligodeoxyribonucleotides, III, NMR and UV spectroscopic studies of the Rp-Rp,Sp-Sp,and Rp-Spduplexes, [d(GG8AATTCC)]2,derived from diastereomeric ethyl phosphorothioates,” Nucleic Acids Research, vol. 14, No. 22, 1986, pp. 9081-9093.
Liang, Hua et al., “Activation of Human B Cells by Phosphorothioate Oligodeoxynucleotides,” J. Clin. Invest. vol. 98, No. 5, Sep. 1996, pp. 1119-1129.
Lipford, Grayson B. et al., “CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants,” Eur J. Immunol. 1997, 27:2340-2344.
Pirotton, Sabine et al., “Adenine Nucleotides Modulate Phosphatidylcholine Metabolism in Aortic Endothelial Cells,” J. or Cellular Physiol. 142:449-457 (1990).
Rodgers, Kathy E. et al., “Investigations into the Mechanism of Immunosuppression Caused by Acute Treatment withO,O,S-Trimethyl Phosphorothioate: Generation of Suppressive Macrophages from Treated Animals,” Toxicol. And Applied Pharmacol. 88, 270-281 (1987).
Ross, Peter et al., “The Cyclic Diguanylic Acid Regulatory System of Cellulose Synthesis inAcetobacter xylinum,” J. of Biol. Chem. vol. 265, Issue of Nov. 5 pp. 18933-18943, 1990.
Connell Y.S. et al., “Anti-tumor activity of a CpG-containing oligodeoxynucleotide (ODN) in athymic mice,”Proceedings of the American Association for Cancer Research Annual Meeting, Mar. 1999, vol. 40, p. 299.

Affiliated with

Also associated with

Rating

Use of stabilized oligonucleotides for preparing a... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of stabilized oligonucleotides for preparing a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of stabilized oligonucleotides for preparing a... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3551250